Joint amicus brief in defense of California law prohibiting anti-competitive generic drug pay-for-delay deals

Description: California enacted a law last fall to clarify and strengthen the prohibition against anti-competitive “pay for delay” agreements, where a brand-name drug maker pays off a generic drug maker to delay introducing its competing generic version. This pay-off enables the brand name to keep charging high prices to consumers. CR strongly supported the California bill, AB 824. Generic drug makers are challenging the new law in court, and CR has joined with the American Antitrust Institute and Public Citizen in submitting a brief to the court as amicus in defense of the law.